康莱特注射液+胸腺法新+分子靶向药物联合立体定向放疗治疗脑转移瘤23例  

KANGLAITE INJECTION COMBINED THYMALFASIN FOR INJECTION AND MOLECULAR TARGETED DRUGS WITH STEREOTACTIC RADIOTHERAPY IN THE TREATMENT OF BRAIN METASTASES OF 23 CASES

作　　者：线胤生[1] 张晓龙[1] 谢丹敏 弓显凤 刘磊[4] 

机构地区：[1]西安交通大学医学院第一附属医院肿瘤外科,陕西省西安市710061 [2]陕西省洛南县医院 [3]西安市结核病胸部肿瘤医院 [4]陕西中医学院中西医结合临床肝胆外科

出　　处：《中国煤炭工业医学杂志》2014年第3期357-360,共4页Chinese Journal of Coal Industry Medicine

摘　　要：目的评价康莱特注射液+胸腺法新+分子靶向药物联合立体定向放疗治疗脑转移瘤的临床疗效。方法将已有明确病理诊断的原发灶癌,经复查头颅CT或磁共振或PET/CT确诊为脑转移瘤的46例患者随机分为治疗组和对照组各23例,其中原发灶癌手术切除术后32例,不能手术或患者拒绝手术14例,每组手术切除术后和没有手术的患者分别为16例、7例。对照组采用全脑放射治疗,治疗组采用立体定向放疗,同时给予康莱特注射液+胸腺法新(基泰)+吉非替尼(gefitinib)。结果治疗组总有效率82.61%,对照组为26.09%,二组比较,差异有统计学意义(P<0.05)。治疗组放疗后头痛症状明显改善,恶心、呕吐反应较轻,KPS评分增加,较对照组比较,差异均有统计学意义(P<0.05)。结论康莱特注射液+胸腺法新+吉非替尼联合立体定向放疗治疗脑转移瘤能明显改善患者的临床症状,降低副作用,提高肿瘤患者的生活质量。Objective To evaluate the clinical effect of Kanglaite Injection ＋ Thymalfasin for Injection ＋ molecular targeted drugs combined with stereotactic radiotherapy for brain metastasis cancer. Methods Totally 46 patients with brain cancer were randomly group, 23 cases in each groupe, including 32 cases of divided into the treatment group and the control primary cancer postoperation, 14 cases not oper-ation or refused operation, eath group the postoperation and no operation patients were 16 people and 7 people. All subjects were diagnosed by the head CT or magnetic resonance or PET/CT and were confirmed as primary cancer by pathology. The control group received a whole brain radiation therapy, the treatment group was treated with stereotactic radiotherapy, while received the Kanglaite Injection ＋ Thymalfasin for Injection （Ji Tai） ＋ gefitinib. Results The total effective rate of treatment group was 82.61% and the control group was 26. 09M, the difference was statistically significant （P〈 0.05）. Symptoms were significantly improved in treatment group after radiotherapy of headache with a slight nausea and vomiting reaction, at the same time the KPS score was increased. Compared with the Control group, the differences were statistically significant （P〈0.05）. Conclusion Kanglaite Injec-tion ＋ Thymalfasin for Injection ＋ gefitinib and combined with stereotactic radiotherapy can be signif-icantly improve the symptoms of patients with brain cancer, reduce the side effects, improve the quali-ty of life for the cancer patients.

关 键 词：康莱特注射液 胸腺法新 脑转移瘤 吉非替尼 立体定向放疗 

分 类 号：R730.5[医药卫生—肿瘤]